Compare RRGB & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RRGB | ADAG |
|---|---|---|
| Founded | 1969 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 84.4M | 254.4M |
| IPO Year | 2002 | 2020 |
| Metric | RRGB | ADAG |
|---|---|---|
| Price | $5.09 | $3.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $9.00 | $8.25 |
| AVG Volume (30 Days) | ★ 467.5K | 106.7K |
| Earning Date | 05-28-2026 | 04-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 73.43 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,315,014,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.46 | $1.44 |
| 52 Week High | $7.52 | $4.75 |
| Indicator | RRGB | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 74.15 | 58.69 |
| Support Level | $3.84 | $3.16 |
| Resistance Level | $5.29 | $3.99 |
| Average True Range (ATR) | 0.40 | 0.35 |
| MACD | 0.11 | 0.05 |
| Stochastic Oscillator | 93.06 | 70.94 |
Red Robin Gourmet Burgers Inc is a restaurant operator. The company develops, operates, and franchises casual-dining restaurants and fast-casual restaurants in North America. The company's brands are Red Robin, Red Robin Gourmet Burgers, Red Robin America's Gourmet Burgers and Spirits, Red Robin Burger Works, YUMMM, Red Robin Gourmet Burgers and Brews, and Red Robin Royalty names and logos. The company's revenue consists of sales from restaurant operations, gift card breakage, franchise royalties and fees, and other miscellaneous revenue. It has one operating and one reportable segment: restaurants.
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.